Transmitted multidrug resistant HIV-1: New and investigational therapeutic approaches

Anita Shet, Martin Markowitz

Research output: Contribution to journalReview article

Abstract

The increasing prevalence of transmitted drug-resislant HIV-1 has highlighted the challenging issue of the optimal management of antiretrodral-naïve, newly infected patients with multidrug-resistant HIV-1. This review discusses current trends in the evolution and transmission of HIV-1 with reduced susceptibility to multiple antiretroviral agents. In most cases, clinical strategies for the management of such patients with stable virological and immunological parameters involve deferment of therapy until clinically indicated. Wien a decision is made to initiate therapy, the process of selecting a regimen should consider baseline viral genotype and phenotype results, as well as the inclusion of novel agents with diverse mechanisms of action, in order to achieve a more complete suppression of viral replication. A summary of established and investigational antiretroviral agents is presented in this review, together with novel therapeutic approaches to decrease the burden of viral replication and maintain immunological status in cases of transmitted multidrug-resistant HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)709-720
Number of pages12
JournalCurrent Opinion in Investigational Drugs
Volume7
Issue number8
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

HIV-1
Anti-Retroviral Agents
Therapeutics
Viral Load
HIV Infections
Genotype
Phenotype
Pharmaceutical Preparations

Keywords

  • Investigational antiretroviral agents
  • Multidrug-resistant HIV-1
  • Therapeatic approach
  • Transmission

ASJC Scopus subject areas

  • Pharmacology

Cite this

Transmitted multidrug resistant HIV-1 : New and investigational therapeutic approaches. / Shet, Anita; Markowitz, Martin.

In: Current Opinion in Investigational Drugs, Vol. 7, No. 8, 08.2006, p. 709-720.

Research output: Contribution to journalReview article

@article{41ad7652a91c4f0b872a917c0c7dcebd,
title = "Transmitted multidrug resistant HIV-1: New and investigational therapeutic approaches",
abstract = "The increasing prevalence of transmitted drug-resislant HIV-1 has highlighted the challenging issue of the optimal management of antiretrodral-na{\"i}ve, newly infected patients with multidrug-resistant HIV-1. This review discusses current trends in the evolution and transmission of HIV-1 with reduced susceptibility to multiple antiretroviral agents. In most cases, clinical strategies for the management of such patients with stable virological and immunological parameters involve deferment of therapy until clinically indicated. Wien a decision is made to initiate therapy, the process of selecting a regimen should consider baseline viral genotype and phenotype results, as well as the inclusion of novel agents with diverse mechanisms of action, in order to achieve a more complete suppression of viral replication. A summary of established and investigational antiretroviral agents is presented in this review, together with novel therapeutic approaches to decrease the burden of viral replication and maintain immunological status in cases of transmitted multidrug-resistant HIV-1 infection.",
keywords = "Investigational antiretroviral agents, Multidrug-resistant HIV-1, Therapeatic approach, Transmission",
author = "Anita Shet and Martin Markowitz",
year = "2006",
month = "8",
language = "English (US)",
volume = "7",
pages = "709--720",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Transmitted multidrug resistant HIV-1

T2 - New and investigational therapeutic approaches

AU - Shet, Anita

AU - Markowitz, Martin

PY - 2006/8

Y1 - 2006/8

N2 - The increasing prevalence of transmitted drug-resislant HIV-1 has highlighted the challenging issue of the optimal management of antiretrodral-naïve, newly infected patients with multidrug-resistant HIV-1. This review discusses current trends in the evolution and transmission of HIV-1 with reduced susceptibility to multiple antiretroviral agents. In most cases, clinical strategies for the management of such patients with stable virological and immunological parameters involve deferment of therapy until clinically indicated. Wien a decision is made to initiate therapy, the process of selecting a regimen should consider baseline viral genotype and phenotype results, as well as the inclusion of novel agents with diverse mechanisms of action, in order to achieve a more complete suppression of viral replication. A summary of established and investigational antiretroviral agents is presented in this review, together with novel therapeutic approaches to decrease the burden of viral replication and maintain immunological status in cases of transmitted multidrug-resistant HIV-1 infection.

AB - The increasing prevalence of transmitted drug-resislant HIV-1 has highlighted the challenging issue of the optimal management of antiretrodral-naïve, newly infected patients with multidrug-resistant HIV-1. This review discusses current trends in the evolution and transmission of HIV-1 with reduced susceptibility to multiple antiretroviral agents. In most cases, clinical strategies for the management of such patients with stable virological and immunological parameters involve deferment of therapy until clinically indicated. Wien a decision is made to initiate therapy, the process of selecting a regimen should consider baseline viral genotype and phenotype results, as well as the inclusion of novel agents with diverse mechanisms of action, in order to achieve a more complete suppression of viral replication. A summary of established and investigational antiretroviral agents is presented in this review, together with novel therapeutic approaches to decrease the burden of viral replication and maintain immunological status in cases of transmitted multidrug-resistant HIV-1 infection.

KW - Investigational antiretroviral agents

KW - Multidrug-resistant HIV-1

KW - Therapeatic approach

KW - Transmission

UR - http://www.scopus.com/inward/record.url?scp=33747617818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747617818&partnerID=8YFLogxK

M3 - Review article

C2 - 16955682

AN - SCOPUS:33747617818

VL - 7

SP - 709

EP - 720

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 8

ER -